Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The intervention showed no clear difference in progression‐free survival (moderate certainty).
The intervention showed no clear difference in overall survival (moderate certainty).
The intervention showed no clear difference in recurrence‐free survival (moderate certainty).
The intervention showed no clear difference in direct surgical morbidity (moderate certainty).
The intervention probably leads to higher surgery‐related systemic morbidity (moderate certainty).
The intervention leads to higher lymphoedema or lymphocyst (high certainty).
Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).
It is very uncertain whether gestrinone changes side effects: hot flushes compared with danazol (very low certainty).
Gestrinone showed no clear difference in side effects: acne compared with danazol (low certainty).
Gestrinone may leads to lower amenorrhoea compared with leuprolin (low certainty).
Gestrinone may leads to higher spotting or bleeding compared with leuprolin (low certainty).
Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).
Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).
Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).
Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).
It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).
It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).
It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).